LawyersAndSettlements.com reported a while ago (Aug. 5th precisely) about the proposed class action settlement in the Vytorin-Zetia case against Merck and Schering-Plough.
At the heart of this case are claims that Vytorin and Zetia were marketed as being more effective than other anti-cholesteral drugs on the market (namely, those drugs in the class known as statins)—and that Vytorin and Zetia were sold at higher prices even though there wasn’t really evidence that they were more effective than less-expensive anti-cholesterol drugs.
For consumers—aka the “Consumer Class” of the Vytorin/Zetia settlement, it means that if you were taking either of these drugs and either paid or were obligated to pay for them between November 1, 2002 and September 17, 2009, you may be eligible to participate in this settlement. Translation: you may be able to get some money back on your purchases as a result of this settlement.
How much money?—it’s the number one question we always get about settlements. Well, as